CognICA(TM) Shown to Save Tens of Millions of Dollars in Healthcare Costs Annually and Improve Patient Outcomes in the UK National Health Service
Vancouver, British Columbia--(Newsfile Corp. - October 24, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTC Pink: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity"), a leader in artificial intelligence (AI) powered cognitive assessment technology, is delighted to announce the peer-reviewed publication of the health economic impact of its CognICATM technology in the journal Frontiers in Public Health. The article is available here: https://www.frontiersin.org/articles/10.3389/fpubh.2023.1240901/abstract. This research evaluated the economic impact and clinical benefits of CognICATM compared to standard cognitive tests for...
2023-10-24 9:00 AM EDT
Cognetivity Neurosciences and UC Health Partner to Improve Early Detection of Cognitive Impairment in USA
Vancouver, British Columbia--(Newsfile Corp. - October 11, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTC Pink: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity"), a leading artificial intelligence (AI) healthcare technology company is delighted to announce a collaboration with UC Health, one of the leading healthcare systems in the United States, to improve early detection of cognitive impairment in clinical settings in the USA. Centred in Cincinnati, Ohio, UC Health is one of the highest rated healthcare providers in the USA. Recognized for...
2023-10-11 9:00 AM EDT
Cognetivity Neurosciences Announces Commercial Agreement with Mediclinic to Provide Cognitive Assessment to Over 50s
Vancouver, British Columbia--(Newsfile Corp. - October 3, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTC Pink: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity"), a leading AI healthcare technology company, is delighted to announce a collaboration with the Mediclinic Group ("Mediclinic"), a prominent international private hospital group operating across Europe, the Middle East and Southern Africa. This pivotal partnership will start in the United Arab Emirates and is set to revolutionize brain health diagnosis and care in the region, effectively addressing the escalating...
2023-10-03 9:24 AM EDT
Cognetivity Neurosciences Partners with No Fear Counselling to Pioneer Brain Health Assessment Through Groundbreaking AI Technology
Vancouver, British Columbia--(Newsfile Corp. - September 21, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity"), a leading artificial intelligence (AI) healthcare technology company is delighted to announce a partnership with No Fear Counselling, the leading and rapidly growing Vancouver-based counselling practice with over 150 therapists and a network of 60 locations. This groundbreaking partnership, utilising Cognetivity's AI powered CognICA technology, promises to usher in a new era of mental well-being by providing cutting-edge tools to...
2023-09-21 9:15 AM EDT
Cognetivity Neurosciences' AI Powered CognICA Platform Wins Major Industry Award
Vancouver, British Columbia--(Newsfile Corp. - September 13, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity"), a leading artificial intelligence (AI) healthcare technology company is delighted to announce that it has won a major AI technology award, with the company's CognICA™ platform being recognised in the CogX Awards as the Best AI Product in Healthcare for 2023. CognICA was chosen as the winner in a strong field of contenders and was recognised for both...
2023-09-13 9:00 AM EDT
Cognetivity Neurosciences' AI Powered CognICA Platform Shortlisted for Major Industry Award
Vancouver, British Columbia--(Newsfile Corp. - September 5, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity"), a leading artificial intelligence (AI) healthcare technology company is pleased to announce that it has been shortlisted for a major AI technology award, with the company's CognICATM platform being recognised in the CogX Awards in the Most Innovative AI Product in the Healthcare category. The CogX awards are part of the CogX Festival, the world's biggest festival of inspiration, impact...
2023-09-05 8:45 AM EDT
Cognetivity Neurosciences Announces Publication of Peer-Reviewed Article Showing Effectiveness of its AI Powered CognICA Technology in Detecting Early-Stage Alzheimer's Disease
Vancouver, British Columbia--(Newsfile Corp. - August 30, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE.1UB) ("the Company" or "Cognetivity") a leading artificial intelligence (AI) healthcare technology company is pleased to announce the peer-reviewed publication of its groundbreaking Accelerating Dementia Pathway Technologies (ADePT) Study in the journal Frontiers in Aging Neuroscience - a leading academic journal on brain aging and associated diseases. The successful project, funded by the UK government innovation agency Innovate UK, was designed to validate the efficacy of...
2023-08-30 8:45 AM EDT
Cognetivity Neurosciences Announces Successful Registration With Health Canada for Clinical use of CognICA(TM) AI-Powered Brain Health Technology in Canada
Vancouver, British Columbia--(Newsfile Corp. - August 2, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity"), a technology company that has created a unique Artificial Intelligence (AI) powered brain health screening and monitoring platform for use in medical, commercial and consumer environments, is delighted to announce that it has completed registration for its groundbreaking CognICA™ cognitive assessment system with Health Canada under Medical Devices Regulations (SOR/98-282). This registration allows the company to market the medical device...
2023-08-02 8:48 AM EDT
New Disease Modifying Drug for Alzheimer's Disease Fully Approved by FDA, Highlighting the Crucial Role for Cognetivity in Early Detection and Monitoring
Vancouver, British Columbia--(Newsfile Corp. - July 7, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity"), a technology company that has created a unique Artificial Intelligence (AI) powered brain health screening and monitoring platform for use in medical, commercial and consumer environments, is delighted to note that Eisai's (TYO: 4523) Leqembi has achieved full FDA approval for the treatment of Alzheimer's disease, news that brings hope to tens of millions of sufferers and at-risk individuals worldwide.Leqembi...
2023-07-07 9:00 AM EDT
Cognetivity Neurosciences Partners with Clairvo to Advance AI Powered Brain Health Management in Japan
Vancouver, British Columbia--(Newsfile Corp. - June 13, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity"), is thrilled to announce a strategic partnership with CLAIRVO TECHNOLOGIES, Inc. (hereinafter, "Clairvo"), a wholly owned subsidiary of Marubeni Corporation (market cap US$ 28bn, TYO: 8002), aimed at revolutionizing brain health and addressing dementia-related challenges in Japan. Leveraging the power of artificial intelligence (AI), this partnership seeks to enhance preventative care and promote healthy aging within the Japanese population. As...
2023-06-13 8:55 AM EDT
Cognetivity Neurosciences AI Platform Technology to Play a Pivotal Role in the Effective Delivery of Newly Approved Alzheimer's Drugs
Vancouver, British Columbia--(Newsfile Corp. - June 6, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE:1UB) ("the Company" or "Cognetivity"), a technology company that has created a unique Artificial Intelligence (AI) powered brain health screening and monitoring platform for use in medical, commercial and consumer environments, is thrilled about the opportunity to facilitate the widespread rollout of recently approved Alzheimer's drugs in the USA following the Centers for Medicare & Medicaid Services' (CMS) agreement to provide coverage for fully approved FDA...
2023-06-06 9:00 AM EDT
Cognetivity Neurosciences Announces Collaboration with Alzheimer's Society to Further Expand its AI Algorithms
Vancouver, British Columbia--(Newsfile Corp. - May 31, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity"), a leading provider of brain health solutions powered by AI, is excited to announce a collaboration with the Alzheimer's Society in Oman. This partnership aims to study cognitive health in patients with dementia and diabetes.Cognetivity Neurosciences is renowned for its innovative Integrated Cognitive Assessment (CognICA) platform, a state-of-the-art tool that combines artificial intelligence and neuroscience to provide rapid, accurate, and...
2023-05-31 8:55 AM EDT
Eli Lilly Releases Positive Results on Latest Disease Modifying Therapeutic for Alzheimer's Disease, Highlighting Need for Cognetivity's CognICA Platform
Vancouver, British Columbia--(Newsfile Corp. - May 9, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity") is pleased to note Eli Lilly & Co.'s results for its experimental drug for Alzheimer's disease, which demonstrated slowing the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval. The drug, donanemab, slowed the disease by 35% over a year and a half in a trial of 1,182 patients with...
2023-05-09 9:23 AM EDT
Cognetivity Neurosciences Announces Agreement with Mitsui Sumitomo Aioi Life Insurance of Japan to Provide CognICA Technology to Customers
Vancouver, British Columbia--(Newsfile Corp. - April 25, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity") has entered into an agreement with Mitsui Sumitomo Aioi Life Insurance ("MSA") to work together to provide Cognetivity's artificial intelligence ("AI") powered technology (CognICATM) to MSA's policyholders through MSA's customer-facing web platform. The two companies will also begin negotiations to conclude a distributorship agreement by the end of June, 2023.MSA is the core company of the Japanese domestic life insurance...
2023-04-25 8:30 AM EDT
Cognetivity Neurosciences Appoints Renowned Life Sciences Leader Karimah Es Sabar as Director
Vancouver, British Columbia--(Newsfile Corp. - April 20, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity"), a technology company that has created a unique brain health assessment platform for use in medical, commercial and consumer environments, is pleased to announce the appointment of Ms. Karimah Es Sabar as a Board Director. Ms. Es Sabar is a highly-recognized life sciences leader with broad international experience, spanning the global biopharmaceutical industry, start-ups, not-for-profit organizations, and venture investment. She...
2023-04-20 8:30 AM EDT
Cognetivity Neurosciences Unveils Groundbreaking Research on Cognition and Sleep, Extends Collaboration with University of Oxford
Vancouver, British Columbia--(Newsfile Corp. - March 23, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity"), a technology company that has created a unique brain health screening platform for use in medical, commercial and consumer environments, is pleased to announce important validation results for the use of its CognICA technology in measuring the impact of changes in sleep patterns on brain health, as well as further collaboration with Oxford University to detect the earliest signs of...
2023-03-23 9:29 AM EDT
Cognetivity Neurosciences Enters Commercial Agreement with UK-Based Brain Health Supplements Provider
Vancouver, British Columbia--(Newsfile Corp. - March 15, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity"), a technology company that has created a unique brain health screening platform for use in medical, commercial and consumer environments, is pleased to announce that it has reached a commercial agreement with brain health supplements provider Conka.Conka is a UK-based provider of natural brain health supplements, geared towards individuals engaging in high-performance sports and other physical activities. Conka's mission is...
2023-03-15 9:30 AM EDT
Cognetivity Neurosciences Publishes Outstanding Results and Expands Deployment With Senior Care Network in Singapore
Vancouver, British Columbia--(Newsfile Corp. - March 8, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity"), a technology company that has created a unique brain health screening platform for use in medical, commercial and consumer environments, is pleased to announce that it is extending the deployment of its CognICA technology with Lions Befrienders Service Association ("Lions Befrienders" or "LBSA"), a leading Singapore-based senior healthcare provider.Established in 1995, Lions Befrienders has addressed the varied needs of...
2023-03-08 8:30 AM EST
Cognetivity Neurosciences Announces Commercial Deployment at Leading Psychiatry and Neurology Centre in UAE
Vancouver, British Columbia--(Newsfile Corp. - February 23, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity"), a technology company that has created a unique brain health screening platform for use in medical, commercial and consumer environments, is pleased to announce that it has reached a commercial agreement with American Center for Psychiatry and Neurology (ACPN) in the United Arab Emirates (UAE).ACPN is a specialist medical facility with branches in the cities of Abu Dhabi, Dubai and...
2023-02-23 8:30 AM EST
Cognetivity Announces Further Scientific Evidence of its AI-Powered CognICA(TM) Platform's Ability to Detect and Monitor Cognitive Impairment in Patients With Multiple Sclerosis
Vancouver, British Columbia--(Newsfile Corp. - February 22, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (FSE: 1UB) (OTCQB: CGNSF) (the "Company" or "Cognetivity") today announced the publication of its latest peer-reviewed scientific paper on its Integrated Cognitive Assessment (ICA) technology in the journal 'Multiple Sclerosis and Related Disorders'. The paper provides further significant evidence of Cognetivity's technology's validity and clinical utility for cognitive assessment in patients with neurological diseases such as multiple sclerosis (MS).The study investigated the link between subjects' performance...
2023-02-22 8:30 AM EST